Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer...

Landmark co-development and commercialization agreement with AstraZeneca for IPH2201 in immuno-oncology Cash and cash equivalents amounting to €279 million following initial payment of $250 million...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its fifth assessment of the EffiKIR study and...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma’s proprietary anti-NKG2A antibody...

The Paoli Calmettes Institute (IPC), a private not-for-profit comprehensive cancer center in Marseille, France, has initiated a collaboration with Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)...

Cash, cash equivalents and financial instruments of the Company amounted to 59.2 million euros as at March 31, 2015 Co-development and commercialization agreement with AstraZeneca including an upfront...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting (“AGM”) which took place on April 27, 2015, in Marseille, France : A number of 27,560,731 votes were...